Key result
The LPLS447X truncation variant significantly enhanced receptor-mediated uptake of lipoproteins by hepatic cells compared to wild-type LPL (p < 0.05), while showing no difference in catalytic activity or inhibition by ANGPTL4.
Why the study?
Does the LPLS447X variant improve lipoprotein uptake or catalytic activity compared to wild-type LPL in vitro?
Population
In vitro biochemical models (purified LPL and LPLS447X dimers, HepG2 and Huh-7 hepatic cell lines)
Comparison
LPLS447X truncation variant vs Wild-type LPL
Design
Preclinical
Authors
Loading...
Should not yet change lipid management; hypothesis-generating for LPL S447X effects and requires in vivo validation.
Does the LPLS447X variant improve lipoprotein uptake or catalytic activity compared to wild-type LPL in vitro?
p-value: p=<0.05
The cardioprotective LPLS447X variant does not have altered catalytic activity but enhances receptor-mediated hepatic uptake of lipoproteins, providing a mechanistic explanation for its beneficial lipid profile.
Hayne et al. (2016) studied Lipoprotein lipase function. LPLS447X variant vs. Wild-type LPL was evaluated on Lipoprotein uptake by hepatic cells (p=<0.05). The LPLS447X truncation variant significantly enhanced receptor-mediated uptake of lipoproteins by hepatic cells compared to wild-type LPL (p < 0.05), while showing no difference in catalytic activity or inhibition by ANGPTL4.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: